Halozyme Therapeutics, Inc.HALONASDAQ
Loading
Operating Expenses Over TimeStrong
Percentile Rank100
3Y CAGR+9.0%
5Y CAGR+32.6%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+9.0%/yr
vs +4.7%/yr prior
5Y CAGR
+32.6%/yr
Recent deceleration
Acceleration
+4.4pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
4.1x
Strong expansion
Streak
5 yr
Consecutive growthStrong
PeriodValueYoY Change
TTM$328.17M+7.8%
2024$304.43M+1.7%
2023$299.32M+18.2%
2022$253.28M+194.5%
2021$86.00M+7.5%
2020$79.97M-63.3%
2019$218.06M+3.3%
2018$211.06M+3.2%
2017$204.46M+3.9%
2016$196.69M-